{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:02:20Z","timestamp":1790899340844,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014091","name":"AstraZeneca Pharma Poland","doi-asserted-by":"publisher","award":["NCT01226316"],"award-info":[{"award-number":["NCT01226316"]}],"id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["AZD5363"],"award-info":[{"award-number":["AZD5363"]}],"id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:p>Pharmacokinetics\u2010matched digital electrocardiogram data (<jats:italic>n<\/jats:italic>\u2009=\u2009503 measurements from 180 patients) collected in a first\u2010in\u2010human, multi\u2010part, dose\u2010escalation (from 80 to 800\u2009mg) and dose expansion (at 480\u2009mg) phase 1 study in patients with advanced solid malignancies, were used to assess potential risk of QT prolongation associated with the AKT inhibitor capivasertib. The relationship between plasma drug concentrations and baseline\u2010adjusted Fridericia\u2010corrected QT (\u0394QTcF) values was estimated using a prespecified linear mixed\u2010effects model. The model provided an unbiased reproduction of the experimental data set, estimating a small but positive correlation between capivasertib concentration and \u0394QTcF. At the expected therapeutic dose (400\u2009mg twice daily) the predicted mean \u0394QTcF at the steady state maximum concentration was 3.97\u2009ms with an upper limit of the 90% CI of 5.07\u2009ms; below the 10\u00a0ms limit proposed by ICH E14 guidance. This analysis suggests that capivasertib is not expected to present a clinically significant risk for QT prolongation that is associated with pro\u2010arrhythmic effects.<\/jats:p>","DOI":"10.1111\/bcp.15006","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T09:35:30Z","timestamp":1627292130000},"page":"858-864","source":"Crossref","is-referenced-by-count":12,"title":["Concentration\u2010QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6383-5334","authenticated-orcid":false,"given":"Veronika","family":"Voronova","sequence":"first","affiliation":[{"name":"M&amp;S Decisions LLC  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1697-972X","authenticated-orcid":false,"given":"Marie","family":"Cullberg","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology BioPharmaceuticals R&amp;D, AstraZeneca R&amp;D  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Delff","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology BioPharmaceuticals R&amp;D, AstraZeneca R&amp;D  Boston MA USA"},{"name":"Vertex Pharmaceuticals  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-5243","authenticated-orcid":false,"given":"Joanna","family":"Parkinson","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology BioPharmaceuticals R&amp;D, AstraZeneca R&amp;D  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Dota","sequence":"additional","affiliation":[{"name":"Cardiovascular Safety Center of Excellence Oncology R&amp;D, AstraZeneca R&amp;D  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Schiavon","sequence":"additional","affiliation":[{"name":"Late Development Oncology Oncology R&amp;D, AstraZeneca R&amp;D  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Maroj","sequence":"additional","affiliation":[{"name":"Patient Safety Oncology, Global Medicines Development AstraZeneca R&amp;D  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinko","family":"Reki\u0107","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology BioPharmaceuticals R&amp;D, AstraZeneca R&amp;D  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Y. Amy","family":"Cheung","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology BioPharmaceuticals R&amp;D, AstraZeneca R&amp;D  Cambridge UK"},{"name":"Certara  Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9258396"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00064"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6854"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11412"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1902"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm301762v"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0824-T"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pathol.4.110807.092311"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2260"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-2987-9"},{"issue":"5","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdz086","article-title":"BEECH: a dose\u2010finding run\u2010in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor\u2010positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub\u2010population","volume":"30","author":"Turner NC","year":"2019","journal-title":"Ann Oncol"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00368"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3558-z"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0433-4"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30817-4"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0143"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1920.tb18266.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-474X.1997.tb00325.x"},{"key":"e_1_2_10_20_1","unstructured":"European Medicines Agency.ICH: E14: The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs\u2014step 5. 2005.https:\/\/www.ema.europa.eu\/en\/ich-e14-clinical-evaluation-qtqtc-interval-prolongation-proarrhythmic-potential-non-antiarrhythmic. Accessed March 5 2021."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9558-5"},{"key":"e_1_2_10_22_1","unstructured":"International Council for Harmonisation E14 Implementation Working Group.ICH E14 guideline: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs. Questions and answers (R3).2015.https:\/\/database.ich.org\/sites\/default\/files\/E14_Q%26As_R3_Q%26As.pdf. Accessed March 5 2021."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-018-9589-6"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14752"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14750"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-018-9582-0"},{"key":"e_1_2_10_27_1","unstructured":"KangD LinK LudwigE YinO.Concentration\u2010QT analysis of quizartinib in patients with relapsed\/refractory AML. Presented at the Annual Meeting of the American Conference on Pharmacometrics; October 7\u201310 2018; San Diego California."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12405"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13832"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1916-9"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13488"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-39053-6_5"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.009"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15006","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:13:57Z","timestamp":1692850437000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/bcp.15006"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15006","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}